Update on the pharmacogenomics of proton pump inhibitors

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Proton pump inhibitors (PPIs) are widely used for the treatment of gastroesophageal reflux disease as well as other acid-related disorders. PPIs are metabolized primarily via the CYP2C19 and CYP3A4 isoenzymes; their activity is influenced both by exogenous and endogenous (pharmacogenetic) factors. The CYP2C19 polymorphism affects the metabolism of PPIs, causing large individual pharmacokinetic variations. Differences in the CYP2C19-mediated metabolism can produce marked interpatient variability in acid suppression, in drug-interaction potential and in clinical efficacy. Understanding the pharmacokinetic properties of PPIs and examining the pharmacogenetic alterations may help clinicians optimize PPI therapy and administer individual treatment, especially to nonresponder patients with gastroesophageal reflux disease or ulcer or after failed eradication therapy.

Original languageEnglish
Pages (from-to)873-888
Number of pages16
JournalPharmacogenomics
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Proton Pump Inhibitors
Pharmacogenetics
Gastroesophageal Reflux
Pharmacokinetics
Cytochrome P-450 CYP3A
Acids
Therapeutics
Drug Interactions
Isoenzymes
Ulcer
Cytochrome P-450 CYP2C19

Keywords

  • gastroesophageal reflux disease
  • Helicobacter pylori
  • peptic ulcer
  • pharmacogenetics
  • pharmacogenomics
  • proton-pump inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Update on the pharmacogenomics of proton pump inhibitors. / Hagymási, K.; Müllner, Katalin; Herszényi, L.; Tulassay, Z.

In: Pharmacogenomics, Vol. 12, No. 6, 06.2011, p. 873-888.

Research output: Contribution to journalArticle

@article{d51933f59fde43e98936e6562393ea3e,
title = "Update on the pharmacogenomics of proton pump inhibitors",
abstract = "Proton pump inhibitors (PPIs) are widely used for the treatment of gastroesophageal reflux disease as well as other acid-related disorders. PPIs are metabolized primarily via the CYP2C19 and CYP3A4 isoenzymes; their activity is influenced both by exogenous and endogenous (pharmacogenetic) factors. The CYP2C19 polymorphism affects the metabolism of PPIs, causing large individual pharmacokinetic variations. Differences in the CYP2C19-mediated metabolism can produce marked interpatient variability in acid suppression, in drug-interaction potential and in clinical efficacy. Understanding the pharmacokinetic properties of PPIs and examining the pharmacogenetic alterations may help clinicians optimize PPI therapy and administer individual treatment, especially to nonresponder patients with gastroesophageal reflux disease or ulcer or after failed eradication therapy.",
keywords = "gastroesophageal reflux disease, Helicobacter pylori, peptic ulcer, pharmacogenetics, pharmacogenomics, proton-pump inhibitor",
author = "K. Hagym{\'a}si and Katalin M{\"u}llner and L. Hersz{\'e}nyi and Z. Tulassay",
year = "2011",
month = "6",
doi = "10.2217/pgs.11.4",
language = "English",
volume = "12",
pages = "873--888",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Update on the pharmacogenomics of proton pump inhibitors

AU - Hagymási, K.

AU - Müllner, Katalin

AU - Herszényi, L.

AU - Tulassay, Z.

PY - 2011/6

Y1 - 2011/6

N2 - Proton pump inhibitors (PPIs) are widely used for the treatment of gastroesophageal reflux disease as well as other acid-related disorders. PPIs are metabolized primarily via the CYP2C19 and CYP3A4 isoenzymes; their activity is influenced both by exogenous and endogenous (pharmacogenetic) factors. The CYP2C19 polymorphism affects the metabolism of PPIs, causing large individual pharmacokinetic variations. Differences in the CYP2C19-mediated metabolism can produce marked interpatient variability in acid suppression, in drug-interaction potential and in clinical efficacy. Understanding the pharmacokinetic properties of PPIs and examining the pharmacogenetic alterations may help clinicians optimize PPI therapy and administer individual treatment, especially to nonresponder patients with gastroesophageal reflux disease or ulcer or after failed eradication therapy.

AB - Proton pump inhibitors (PPIs) are widely used for the treatment of gastroesophageal reflux disease as well as other acid-related disorders. PPIs are metabolized primarily via the CYP2C19 and CYP3A4 isoenzymes; their activity is influenced both by exogenous and endogenous (pharmacogenetic) factors. The CYP2C19 polymorphism affects the metabolism of PPIs, causing large individual pharmacokinetic variations. Differences in the CYP2C19-mediated metabolism can produce marked interpatient variability in acid suppression, in drug-interaction potential and in clinical efficacy. Understanding the pharmacokinetic properties of PPIs and examining the pharmacogenetic alterations may help clinicians optimize PPI therapy and administer individual treatment, especially to nonresponder patients with gastroesophageal reflux disease or ulcer or after failed eradication therapy.

KW - gastroesophageal reflux disease

KW - Helicobacter pylori

KW - peptic ulcer

KW - pharmacogenetics

KW - pharmacogenomics

KW - proton-pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79959396924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959396924&partnerID=8YFLogxK

U2 - 10.2217/pgs.11.4

DO - 10.2217/pgs.11.4

M3 - Article

VL - 12

SP - 873

EP - 888

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 6

ER -